Cargando…

Effects of viral load on tenofovir vs. entecavir efficacy in recurrence prevention of hepatitis B virus-related hepatocellular carcinoma

Detalles Bibliográficos
Autores principales:	Qi, Weili, Shen, Junyi, Zhang, Yu, Gao, Fengwei, Li, Chuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Clinical Observation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538913/ https://www.ncbi.nlm.nih.gov/pubmed/36729999 http://dx.doi.org/10.1097/CM9.0000000000002433

Ejemplares similares

Tenofovir vs. entecavir on recurrence of hepatitis B virus-related hepatocellular carcinoma beyond Milan criteria after hepatectomy
por: Shen, Junyi, et al.
Publicado: (2022)

Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis
por: Cheung, Ka Shing, et al.
Publicado: (2020)

Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation
por: Hu, Zili, et al.
Publicado: (2022)

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
por: Lee, Sung Won, et al.
Publicado: (2021)

Comparable efficacy with entecavir monotherapy and tenofovir–entecavir combination in chronic hepatitis B patients
por: Baqai, Sumbella, et al.
Publicado: (2015)

Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations
por: Choe, Won Hyeok, et al.
Publicado: (2019)

Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea
por: Choi, HeeKyoung, et al.
Publicado: (2021)

Tenofovir over Entecavir on Hepatocellular Carcinoma Prevention: Potential Mechanisms and Suitable Population
por: Huang, Yongfa, et al.
Publicado: (2022)

The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial
por: Peng, Wei, et al.
Publicado: (2023)

Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate
por: Ha, Yeonjung, et al.
Publicado: (2020)

Meta-analysis of the occurrence of hepatocellular carcinoma after the treatment of entecavir and tenofovir for chronic hepatitis B
por: Tang, Kaiyue, et al.
Publicado: (2023)

No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis
por: Yuan, Jie, et al.
Publicado: (2021)

Entecavir+tenofovir vs. lamivudine/telbivudine+adefovir in chronic hepatitis B patients with prior suboptimal response
por: Woo, Hyun Young, et al.
Publicado: (2020)

Tenofovir versus entecavir on decreasing risk of HBV-related hepatocellular carcinoma recurrence after liver transplantation
por: Yang, Jianming, et al.
Publicado: (2023)

Tenofovir vs Entecavir Among Patients With HBV-Related HCC After Resection
por: Li, Pengpeng, et al.
Publicado: (2023)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
por: Itokawa, Norio, et al.
Publicado: (2020)

Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus: A Reconstructed Individual Patient Data Meta-analysis
por: Tan, Darren Jun Hao, et al.
Publicado: (2022)

Tenofovir versus entecavir on the prognosis of hepatitis B-related hepatocellular carcinoma after surgical resection: a randomised controlled trial
por: Linye, He, et al.
Publicado: (2023)

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir
por: Kim, David Sooik, et al.
Publicado: (2019)

Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis
por: Lee, Soon Kyu, et al.
Publicado: (2017)

Tenofovir versus Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma After FOLFOX-Hepatic Arterial Infusion Chemotherapy
por: Zheng, Zhikai, et al.
Publicado: (2023)

Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B
por: Chang, Te-Sheng, et al.
Publicado: (2021)

Comparison of the Efficacy of Entecavir and Tenofovir in Nucleos(T)ide Analogue-Experienced Chronic Hepatitis B Patients
por: Cho, Eun Ju, et al.
Publicado: (2015)

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
por: Jeon, Hee-Jeong, et al.
Publicado: (2017)

Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy
por: Huang, Chih-Wen, et al.
Publicado: (2023)

868: PREVENTING HEPATCELLULAR CARCINOMA WITH TENOFOVIR VS ENTECAVIR: AN INDIVIDUAL PATIENT DATA META-ANALYSIS OF PROPENSITY SCORE MATCHED STUDIES
por: Tan, Darren J., et al.
Publicado: (2022)

Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients
por: Luo, Hao, et al.
Publicado: (2019)

TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma
por: Lu, Haohao, et al.
Publicado: (2023)

Efficacy of entecavir and tenofovir in chronic hepatitis B under treatment in the public health system in southern Brazil
por: Pereira, Camila V, et al.
Publicado: (2016)

Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients
por: Park, Ji Won, et al.
Publicado: (2017)

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
por: Park, Jung Gil, et al.
Publicado: (2015)

Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection
por: Yang, Young-Mo, et al.
Publicado: (2017)

Virologic Response and Safety of Tenofovir Versus Entecavir in Treatment-Naïve Chronic Hepatitis B patients
por: Yu, Hyung Min, et al.
Publicado: (2015)

Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment
por: Ma, Te-Ling, et al.
Publicado: (2019)

Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B
por: Ishido, Shun, et al.
Publicado: (2023)

Efficacy Comparison of Tenofovir and Entecavir in HBeAg-Positive Chronic Hepatitis B Patients with High HBV DNA
por: Shi, Hong, et al.
Publicado: (2016)

Efficacy and Safety of Peginterferon α-2a and Entecavir Tenofovir in the Treatment of Chronic Hepatitis B Genotype C
por: Yu, Jiao, et al.
Publicado: (2022)

Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA
por: Kim, Dong Hyun, et al.
Publicado: (2017)

Safety of elective hepatectomy performed on weekend for patients with hepatocellular carcinoma
por: Dai, Junlong, et al.
Publicado: (2022)

Laboratory Evaluation of Three Regimens of Treatment of Chronic Hepatitis B: Tenofovir, Entecavir and Combination of Lamivudine and Adefovir
por: Jayakumar, Rajeswari, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_pofgu51fl24gnje85k9e598g74